US Indices
Take Profit
ProShares Ultra Nasdaq Biotechnology seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the NASDAQ Biotechnology Index. This ETF seeks a return of 200% of the return of an index (target) for a single day. The NASDAQ Biotechnology Index is a modified capitalization weighted index that includes securities of The NASDAQ Stock Market listed companies that are classified as either biotechnology or pharmaceutical.


Our leveraged Biotech ETF (BIB) has hit our second Take Profit target at $51.80. Our Buy alert was posted on December 2016 at $41.80 and provided us a $10.0 move, a 24% gain!!!


As predicted, the Biotech industry has finally starting to catch up with the rest of the market. Our BIB BUY Signal at the $40.0 level has finally
hit the first Take Profit level at $48.dollar and continued higher. The trade provided gains of 20% !!!
If you continue to hold to our second take profit level, remember to manage risk and protect your profits.




Our leveraged  BIOTECHNOLOGY ETF (BIB) continue to move higher, while the market continues to move sideways. As predicted the Biotechnology sector is catching up with the Nasdaq index; adding another 2% just yesterday,
The trade is very profitable to our subscribers, which entered the trade at the $40 level, now $46.50 and just $1.5 away from our Take Profit level.
At this point, you should monitor the trade closely, manage your risk and protect your profits.


The Biotech ETF (BIB) is responding well to our BUY signal from 12-12-2016 at support level $40.80. Today the ETF is gaining some momentum and we look forward to the biotech industry to catch up with other major indices. Today the ETF is trading north of $43.0, less than 5 points away from our first Take Profit level. The ETF still looks attractive for new buyers and as always manage your risk and protect your profits.


The Biotech ETF ( BIB) has been struggling and not participating in the market rally we have since the election of Donald Trump. Much of the biotech sector pressure was due to Clinton campaign against high drug prices. We believe that the sector will soon start participating and suggest buying BIB at current depressed prices ($41.0+ dollar level). Set a Take Profit targets at the $48.0  and $51.80 price level.